Obsidian Therapeutics raised $160.5M in a Series C financing led by Wellington Management to drive OBX-115 clinical development.
Obsidian Therapeutics raised $160.5M in a Series C financing led by Wellington Management to drive OBX-115 clinical development.
04/03/24, 12:09 PM
Location
cambridgeMoney raised
$161 million
Industry
therapeutics
health care
biotechnology
Round Type
series c
Investors
Surveyor Capital, Samsara Bio Capital, Tcgx, Ra Capital Management, Logos Capital, Deep Track Capital, Bristol Myers Squibb, Blue Owl Healthcare Opportunities, Atlas Venture, Woodline Partners Lp, T. Rowe Price Associates, Inc., Rtw Investments, Paradigm Bio Capital, Novo Holdings A/S, Janus Henderson Investors, Foresite Capital, Wellington Management
Obsidian Therapeutics, Inc. announced the closure of a significantly oversubscribed $160.5 million Series C financing to advance its lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). The financing was led by top-tier syndicate of life science investors including Wellington Management.
Company Info
Location
1030 massachusetts avenue
cambridge, massachusetts, united states
Additional Info
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.